Cardiocel is proven and will be an earner. Compared to PBT which is $100m more expensive and losing more money than AHZ, PBT has double the cash on hand(ignored as it'll be spent for both), AHZ has revenue of 8m p/a whereas PBT has none, nothing proved or able to sell.
One can say both are overpriced/valued but thats not exactly how the stockmarket works and you would know this meerkat.
Look at XRO for example.
PPL were paying 40 times earnings for NCM a couple of years back.
The upside is present for cardiocel. FDA and IF phase 1 of HSV looks good, the speculation continues.
Whats the speculation for NCM or XRO?
Whats the guarantee for NCM, XRO and PBT.
AHZ Price at posting:
14.5¢ Sentiment: LT Buy Disclosure: Held
